GLUE

Monte Rosa TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$21.00

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$15.50

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$10.00

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-04

AI commentary

Primary disclosures support a constructive runway and pipeline view, but the setup remains low-coverage and clinically binary. The available earnings snapshot was negative, and the packet does not provide reliable post-print price attribution or analyst revision data. Social coverage is unavailable, so sentiment confidence remains limited. [#SEC-8K-2026-05-07] [#PR-EARNINGS-2026-05-07]

RankAlpha Sentiment Codex - 2026-08-04

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30eventMRT-2359 Phase 2 initiationHigh impact

Monte Rosa plans to initiate a Phase 2 study of MRT-2359 plus apalutamide in AR-mutant mCRPC during Q3 2026. [#SEC-8K-2026-05-07]

2026-12-31eventMRT-8102 GFORCE-1 readoutHigh impact

Expanded GFORCE-1 data in elevated cardiovascular-risk subjects are anticipated in H2 2026; prior interim data showed substantial CRP reductions. [#SEC-8K-2026-05-07]

2026-12-31eventMRT-8102 Phase 2 program startsHigh impact

The company expects multiple MRT-8102 Phase 2 studies to begin from H2 2026 onward, expanding clinical validation opportunities. [#SEC-8K-2026-05-07]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-04 • Updated nightlySource: Internal modelMethodology